Humanigen, Inc. (HGEN)
Market Cap | 22.96M |
Revenue (ttm) | 3.33M |
Net Income (ttm) | -108.66M |
Shares Out | 119.08M |
EPS (ttm) | -1.46 |
PE Ratio | n/a |
Forward PE | 9.39 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 3,590,635 |
Open | 0.193 |
Previous Close | 0.184 |
Day's Range | 0.190 - 0.205 |
52-Week Range | 0.090 - 4.110 |
Beta | -1.01 |
Analysts | Sell |
Price Target | 3.28 (+1,601.25%) |
Earnings Date | Feb 27, 2023 |
About HGEN
Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with COVID-19 for which it has completed a Phase 3 study and is the focus of a Phase 2/3 study sponsored by the NIH. It is also developing lenzilumab, which is also being studied in conjunction with CD19-tar... [Read more]
Financial Performance
In 2021, Humanigen's revenue was $3.60 million, an increase of 1052.24% compared to the previous year's $312,000. Losses were -$236.65 million, 164.3% more than in 2020.
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for HGEN stock is "Sell." The 12-month stock price forecast is $3.28, which is an increase of 1,601.25% from the latest price.
News

Humanigen Reports Third Quarter 2022 Financial Results
Short Hills, New Jersey--(Newsfile Corp. - November 14, 2022) - Humanigen, Inc. (Nasdaq: HGEN) (Humanigen), a clinical-stage biopharmaceutical company focused on developing lenzilumab (LENZ®), a first...

Humanigen Announces Participation and Presentation at Jefferies London Healthcare Conference
Short Hills, New Jersey--(Newsfile Corp. - November 10, 2022) - Humanigen, Inc. (Nasdaq: HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on preventing and treating certain infl...

Humanigen Announces Retention of SC&H Capital as Financial Advisor
Short Hills, New Jersey--(Newsfile Corp. - October 31, 2022) - Humanigen, Inc. (Nasdaq: HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on preventing and treating certain infla...

HGEN ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of October 25, 2022 in the Class Action Filed on Behalf of Humanigen, Inc. Shareholders
NEW YORK , Oct. 25, 2022 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Humanigen, Inc. (NASDAQ: HGEN) alleging that the Company...

HGEN LAWSUIT ALERT: Levi & Korsinsky Notifies Humanigen, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
New York, New York--(Newsfile Corp. - October 24, 2022) - Levi & Korsinsky, LLP notifies investors in Humanigen, Inc. ("Humanigen" or the "Company") (NASDAQ: HGEN) of a class action securities lawsuit...

HGEN DEADLINE TOMORROW: ROSEN, SKILLED INVESTOR COUNSEL Encourages Humanigen, Inc. Investors With Losses Exceeding $100K to Secure Counsel Before Important Tuesday Deadline in Securities Class Action - HGEN
NEW YORK , Oct. 24, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Humanigen, Inc. (NASDAQ: HGEN) between May 16, 2020 and July 12...

CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Humanigen Investors of a Lead Plaintiff Deadline of October 25, 2022
NEW YORK , Oct. 24, 2022 /PRNewswire/ -- Attention Humanigen, Inc. ("Humanigen") (NASDAQ: HGEN) shareholders: The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on beha...

Humanigen Class Action: Levi & Korsinsky Reminds Humanigen, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 25, 2022 - HGEN
New York, New York--(Newsfile Corp. - October 23, 2022) - Levi & Korsinsky, LLP notifies investors in Humanigen, Inc. ("Humanigen" or the "Company") (NASDAQ: HGEN) of a class action securities lawsuit...

HGEN FINAL DEADLINE: ROSEN, A TOP RANKED FIRM, Encourages Humanigen, Inc. Investors With Losses Exceeding $100K to Secure Counsel Before Important Tuesday Deadline in Securities Class Action - HGEN
New York, New York--(Newsfile Corp. - October 22, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Humanigen, Inc. (NASDAQ: HGEN) between May 16,...

HGEN SHAREHOLDER ALERT: Jakubowitz Law Reminds Humanigen Shareholders of a Lead Plaintiff Deadline of October 25, 2022
NEW YORK , Oct. 21, 2022 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Humanigen, Inc. (NASDAQ: HGEN). To receive upd...

HUMANIGEN, INC. (HGEN) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Humanigen, Inc. (HGEN)
Did you lose money on investments in Humanigen? If so, please visit Humanigen, Inc. Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or pallocco@bernlieb.com to discuss your...

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Humanigen, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 25, 2022 - (NASDAQ: HGEN)
NEW YORK , Oct. 19, 2022 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Humanigen, Inc.. Shareholders who purchased shares of HGEN during the class period listed are...

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment Humanigen, Inc. of Class Action Lawsuit and upcoming Deadline - HGEN
NEW YORK , Oct. 19, 2022 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Humanigen, Inc. ("Humanigen" or the "Company") (NASDAQ: HGEN) and certain of its off...

GLOBALLY RECOGNIZED ROSEN LAW FIRM Encourages Humanigen, Inc. Investors to Secure Counsel Before Important October 25 Deadline in Securities Class Action – HGEN
NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Humanigen, Inc. (NASDAQ: HGEN) between May 28, 2021 and July 12, 2022, both d...

ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Humanigen, Inc. Investors to Secure Counsel Before Important October 25 Deadline in Securities Class Action - HGEN
NEW YORK , Oct. 18, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Humanigen, Inc. (NASDAQ: HGEN) between May 28, 2021 and July 12...

ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Humanigen, Inc. Investors With Losses to Secure Counsel Before Important October 25 Deadline in Securities Class Action - HGEN
New York, New York--(Newsfile Corp. - October 15, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Humanigen, Inc. (NASDAQ: HGEN) between May 28,...

Humanigen Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before October 25, 2022 to Discuss Your Rights - HGEN
New York, New York--(Newsfile Corp. - October 14, 2022) - Levi & Korsinsky, LLP notifies investors in Humanigen, Inc. ("Humanigen" or the "Company") (NASDAQ: HGEN) of a class action securities lawsuit...

ROSEN, Leading Investor Counsel, Encourages Humanigen, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - HGEN
New York, New York--(Newsfile Corp. - October 11, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Humanigen, Inc. (NASDAQ: HGEN) between May 28,...

ROSEN, Top Ranked Investor Counsel, Encourages Humanigen, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - HGEN
New York, New York--(Newsfile Corp. - October 9, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Humanigen, Inc. (NASDAQ: HGEN) between May 28, ...

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Humanigen, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - HGEN
NEW YORK , Oct. 7, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Humanigen, Inc. (NASDAQ: HGEN) between May 28, 2021 and July 12,...

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Humanigen, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - HGEN
New York, New York--(Newsfile Corp. - October 1, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Humanigen, Inc. (NASDAQ: HGEN) between May 28, ...

ROSEN, A TOP RANKED FIRM, Encourages Humanigen, Inc. Investors With Losses to Secure Counsel Before Important Deadline in Securities Class Action - HGEN
NEW YORK , Sept. 30, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Humanigen, Inc. (NASDAQ: HGEN) between May 28, 2021 and July ...

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on Their Investment Humanigen, Inc. of Class Action Lawsuit and upcoming Deadline - HGEN
New York, New York--(Newsfile Corp. - September 29, 2022) - Pomerantz LLP announces that a class action lawsuit has been filed against Humanigen, Inc. ("Humanigen" or the "Company") (NASDAQ: HGEN) and...

HGEN INVESTOR NEWS: ROSEN, A RANKED AND LEADING FIRM, Encourages Humanigen, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - HGEN
New York, New York--(Newsfile Corp. - September 26, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Humanigen, Inc. (NASDAQ: HGEN) between May 2...

SHAREHOLDER ALERT: Holzer & Holzer Announces a Class Action Was Filed on Behalf of Humanigen (HGEN) Investors and Encourages Investors With Significant Losses to Contact the Firm
Atlanta, Georgia--(Newsfile Corp. - September 22, 2022) - Holzer & Holzer, LLC informs investors that a class action lawsuit was filed against Humanigen, Inc. ("Humanigen" or the "Company") (NASDAQ: H...